Yakovtsova I. I., Ivakhno I. V., Hryhorenko V. R.

PATHOMORPHOLOGY

Scentific article

Ovarian cancer (OC) ranks 8th in the global structure of female mortality from malignant neoplasms. In Ukraine, this indicator ranks 6th among 10 leading causes of death from cancer. In 2019, 1,713 women died from OC due to the diagnosis of tumors in the neglected stages. According to the National Cancer Registry of Ukraine, almost half of all cancer patients were diagnosed with stage III disease. The most common histological type of OC is high-grade serous carcinoma (HGSC), which occupies 70% of all epithelial neoplasms of the female gonads. To date, no effective ways to predict recurrence have been found in the study of HGSC clinical morphological and immunohistochemical (IHC) features. In recent years, many scientists have paid considerable attention to study of the pool of ovarian cancer stem cells (OCSC), as there are many reports in which this cell population plays leading role in metastasis, tumor progression and resistance of tumors to chemotherapy. The aim of the study was studying of CD133 and Sox2 expression as OCSC markers, as well as analyzing the clinical and morphological features of HGSC to determine the possibility of their addition to the IHC panel of prognostic markers of serous ovarian cancer recurrence. Materials and methods of research. We studied the expression of CD133 and Sox2 in 107 cases of HGSC. The study included 26 cancers without recurrence and 81 tumors with recurrence over the next 24 months. The material for the study were paraffin blocks and slides of 107 patients with HGSC stage II-IV disease according to FIGO. The data of pathohistological conclusions of patients are also analyzed. The IHC method was used to study the expression of CD133 and Sox2 markers. Research results. The study found that recurrences were observed in women with stage III-IV (p=0.0006). Also recurrent tumors was characterized by expression level of OCSC markers Sox2 (p=0.0001) and CD133 (p<0.00001) more than 10%. CD133 was expressed in 85.19% of recurrent tumors, and Sox2 in 76.54% of cases. No age correlation was found for CD133, but it was found with disease stage (p<0.001) and recurrence (p<0.001). For Sox2, a direct correlation was also found with stage (p=0.018) and recurrence (p<0.001). It was also found that as the expression level of Sox2 increases with increasing of level of CD133 (p<0.001). Conclusions. Stage III-IV disease should be considered as prognostic clinical marker of recurrence. Expression levels >10% of OCSC markers Sox2 and CD133 should also be considered predictors of recurrence. The relationship between the levels of the IHC-label of two markers we studied indicates commonality of molecular mechanisms and signaling pathways in HGSC tumor progression and recurrence.

ovaries, ovarian carcinoma, recurrence, serous ovarian cancer, immunohistochemistry, Sox2, CD133, FIGO

1. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International Journal of Molecular Science. 2019;20(4):952.
2. World Health Organization, International Agency for Research on Cancer. WHO classification of tumors. Volume 4, Female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020. р. 45.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicans. 2021 May 1;71(3):209-49.
4. NKRU. Rak v Ukrayini, 2019-2020 [Internet]. 2021 [cited 2021 Oct 21]. Dostupno: http://www.ncru.inf.ua/publications/BULL_22/index.htm. [in Ukrainian].
5. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Annals of Oncology. 2013;24:16-21.
6. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: A review. Gynecologic Oncology. 2016;143:433-8.
7. Fischer AK, Pham DL, Bösmüller H, Lengerke C, Wagner P, Bachmann C et all. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors. Virchows Archiv. 2019 Oct;475(4):479-488.
8. Križanac DK, Arapović AK, Skočibušić S, Pintarić I, Trgo G, Tomić S. CD44 Immunoexpression is Unfavorable Predictor in Ovarian Serous Cancer. Applied Immunohistochemistry & Molecular Morphology. 2018 Jul 1;26(6):398-402.
9. Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. Journal of Drug Targeting. 2019;27:257-69.
10. Dorsett KA, Jones RB, Ankenbauer KE, Hjelmeland AB, Bellis SL. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells. Journal of Ovarian Research. 2019 Oct 14;12(1):93.
11. Pham DL, Scheble V, Bareiss P, Fischer A, Beschorner C, Adam A, et al. SOX2 expression and prognostic significance in ovarian carcinoma. International Journal of Gynecological Pathology. 2013 Jul;32(4):358-67.
12. Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, et al. Ovarian Cancer Stem Cell Heterogeneity. Advances in Experimental Medicine and Biology. 2019;1139:201-221.
13. Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H. Expression of Sox2 in human ovarian epithelial carcinoma. Journal of Cancer Research and Clinical Oncology. 2011 Jan;137(1):131-7.
14. Robinson M, Gilbert SF, Waters JA, Lujano-Olazaba O, Lara J, Alexander LJ, et al. Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers (Basel). 2021 Jan 12;13(2):262.

«Bulletin of problems biology and medicine» Issue 4 (162), 2021 year, 291-296 pages, index UDK 611.018.1″712.4″:618.11-006.6-036.87]-091.8-076-036

10.29254/2077-4214-2021-4-162-291-296